文献速递乳腺癌

纵向转录组分析预测三阴性乳腺癌新辅助化疗联合免疫治疗反应:NeoTRIPaPDL1试验结果

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.
PubMed 文献 · Ann Oncol · 2026-05-19

NeoTRIPaPDL1随机III期试验纳入280例高危三阴性乳腺癌患者,比较新辅助卡铂+白蛋白紫杉醇联合或不联合阿替利珠单抗,并对基线和第二周期第一天活检行纵向RNA测序。基线增殖高、基质和代谢低与联合组pCR率升高相关;治疗中活检无肿瘤细胞强烈预测pCR;治疗中免疫和基质特征升高、增殖降低,且在pCR者中更明显。

要点

  • 基线高增殖、低基质和低代谢特征与化疗联合免疫治疗组pCR率升高相关。
  • 治疗中活检无肿瘤细胞强烈预测手术pCR,支持反应引导的新辅助策略。
  • 治疗中免疫相关特征成为反应主要相关因素,基线代谢特征多失去预测价值。

核心结论

  • 纵向转录组分析揭示三阴性乳腺癌新辅助治疗中肿瘤和微环境的动态重塑。
  • 基线肿瘤内在特征与早期治疗诱导的免疫激活提供互补信息,可预测化疗联合免疫治疗反应。
  • 治疗中活检早期肿瘤清除是pCR的强替代指标,支持研究反应引导的新辅助策略。

研究设计与样本

  • 随机III期NeoTRIPaPDL1试验中,280例高危三阴性乳腺癌患者接受新辅助卡铂+白蛋白紫杉醇(CT,n=142)或联合阿替利珠单抗(CT/A,n=138)。
  • 基线和第二周期第一天收集肿瘤活检,行纵向RNA测序评估标志性、免疫和铁死亡相关基因特征。
  • 采用单变量逻辑回归和多变量XGBoost模型评估与病理完全缓解(pCR)的关联。

主要发现

  • 基线时,CT/A组中增殖高、基质和代谢程序低与pCR率升高相关。
  • 治疗中活检无肿瘤细胞在两组均强烈预测手术pCR。
  • 治疗中较基线增殖降低、免疫和基质特征升高,在达到pCR的肿瘤中更明显,尤其化疗免疫治疗患者。
  • 免疫去卷积分析证实治疗中肿瘤微环境动态重塑,反应相关免疫细胞群富集和肿瘤上皮成分减少。
  • 基线时多个代谢特征与结局相关,但治疗中多数失去预测价值,免疫相关程序成为反应主要相关因素。

临床怎么用

  • 基线肿瘤内在特征联合早期治疗中免疫激活可辅助预测三阴性乳腺癌化疗联合免疫治疗反应。
  • 治疗中活检无肿瘤细胞可作为pCR的强替代指标,支持反应引导的新辅助治疗策略研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triple-negative breast cancer (TNBC) is immunogenic, but only a subset of patients benefits from neoadjuvant immune checkpoint inhibitors combined with chemotherapy. Predictive biomarkers to guide patient selection and treatment adaptation are lacking. PATIENTS AND METHODS: In the randomized phase III NeoTRIPaPDL1 trial, 280 patients with high-risk TNBC received neoadjuvant carboplatin plus nab-paclitaxel (CT, n = 142) or the same regimen with atezolizumab (CT/A, n = 138). Tumor biopsies were collected at baseline and on the first day of the second cycle (D1C2). Longitudinal RNA sequencing was performed to evaluate hallmark, immune, and ferroptosis-related gene signatures. Associations with pathologic complete response (pCR) were assessed using univariable logistic regression and multivariable XGBoost models. RESULTS: At baseline, in the CT/A arm, higher proliferation and lower stromal and metabolic programs were associated with increased pCR rate. Absence of tumor cells in early on-treatment biopsies strongly predicted surgical pCR in both treatment arms. Comparison of on-treatment with baseline samples revealed a reduced proliferation and increased immune and stromal signatures. These changes were more pronounced in tumors achieving pCR, particularly in patients receiving chemoimmunotherapy. Immune deconvolution analyses confirmed dynamic remodeling of the tumor microenvironment during treatment, with response-associated enrichment of immune cell populations and reduction of tumor epithelial fractions. Although several metabolic signatures were associated with outcome at baseline, most lost predictive value on-treatment, where immune-related programs became the dominant correlates of response. Exploratory multivariable analyses suggested complementary contributions of on-treatment cytotoxic immune activity and iron metabolism in shaping response to chemoimmunotherapy. CONCLUSIONS: Longitudinal transcriptomic profiling revealed dynamic tumor and microenvironment remodeling during neoadjuvant therapy in TNBC. Baseline tumor-intrinsic features and early treatment-induced immune activation provide complementary information for predicting response to chemoimmunotherapy. Early tumor clearance in on-treatment biopsies represents a strong surrogate of pCR and supports investigation of response-adapted neoadjuvant strategies.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Dugo M, Huang CS, Egle D, et al. Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial. Ann Oncol. 2026. PMID: 42162664. doi:10.1016/j.annonc.2026.05.694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。